128194-13-8
Chemical Structure
(R)-Efonidipine
Synonym(s): (R)-NZ-105; (-)-Efonidipine
- CAS No.: 128194-13-8
- Formula:C34H38N3O7P
- Molecular Weight:631.66
InChIKey: NSVFSAJIGAJDMR-WJOKGBTCSA-N
SMILES: O=C(C1=C(C)NC(C)=C(P2(OCC(C)(CO2)C)=O)[C@@H]1C3=CC([N+]([O-])=O)=CC=C3)OCCN(C4=CC=CC=C4)CC5=CC=CC=C5
Biological Activity: (R)-Efonidipine ((R)-NZ-105) is an orally active, selective T-type Ca2+ channel blocker. (R)-Efonidipine does not inhibit high-voltage-activated Ca2+ channels, voltage-dependent Na+ channels, or Ca2+-activated K+ channels. (R)-Efonidipine modulates cardiac autonomic function by increasing parasympathetic activity and decreasing sympathetic activity. (R)-Efonidipine significantly improves survival in a mouse model of dilated cardiomyopathy. (R)-Efonidipine can be used in research on ischemic encephalopathy, heart failure, and hypertension[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Efonidipine | (R)-Efonidipine ((R)-NZ-105) is an orally active, selective T-type Ca2+ channel blocker. (R)-Efonidipine does not inhibit high-voltage-activated Ca2+ channels, voltage-dependent Na+ channels, or Ca2+-activated K+ channels. (R)-Efonidipine modulates cardiac autonomic function by increasing parasympathetic activity and decreasing sympathetic activity. (R)-Efonidipine significantly improves survival in a mouse model of dilated cardiomyopathy. (R)-Efonidipine can be used in research on ischemic encephalopathy, heart failure, and hypertension. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shin MC, et al. A selective T-type Ca2+ channel blocker R(-) efonidipine. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):411-21.
- [2]. Kinoshita H, et al. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure. Circulation. 2009 Sep 01;120(9):743-52.
- [3]. Furukawa T, et al. Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. British journal of pharmacology. 2004 Dec;143(8):1050-7.
